Table 1. Baseline characteristics of patients stratified by type of OACs.
| DOAC group (n = 45) | WF group (n = 36) | P value | |
|---|---|---|---|
| Age, years | 72.8±7.7 | 73.8±9.0 | 0.608 |
| Male, n(%) | 25 (55.6%) | 19 (52.8%) | 0.803 |
| Hypertension, n(%) | 25 (55.6%) | 20 (55.6%) | 0.999 |
| Diabetes, n(%) | 6 (13.3%) | 8 (22.2%) | 0.293 |
| Dyslipidemia, n(%) | 11 (24.4%) | 7 (19.4%) | 0.591 |
| Prior stroke/TIA | 8 (17.8%) | 8 (22.2%) | 0.617 |
| Systolic blood pressure, mmHg | 132.7±15.9 | 135.5±13.5 | 0.435 |
| Serum glucose, mg/dL | 128.4±60.1 | 139.8±52.9 | 0.373 |
| eGFR < 60 ml/min/1.73 m2, n(%) | 20 (44.4%) | 15 (41.7%) | 0.802 |
| BNP, pg/mL | 176[97–265] | 192[130–430] | 0.396 |
| CHADS2 score | 3[3–4] | 4[3–5] | 0.070 |
| CHA2DS2-VASc score | 4[3–6] | 5[4–6] | 0.266 |
| NIHSS at admission | 4[2–10] | 5[2–9] | 0.877 |
| Baseline CMBs, n(%) | 11 (24.4%) | 8 (22.2%) | 0.815 |
| PVH or DWMH > grade 1, n(%) | 8 (17.8%) | 12 (33.3%) | 0.107 |
| Multiple SLIs, n(%) | 15(33.3%) | 13(36.1%) | 0.794 |
| Antiplatelet drug use, n(%) | 5 (11.1%) | 8 (22.2%) | 0.176 |
| Antihypertensive drug use, n(%) | 22 (48.9%) | 16 (44.4%) | 0.690 |
| Statin use, n(%) | 17 (37.8%) | 8 (22.2%) | 0.132 |
| Time from stroke onset to start of OACs, days | 5[2–9] | 6[3–8] | 0.993 |
| Follow-up period, months | 31[17–50] | 37[20–59] | 0.124 |
Data are expressed as the mean ±SD or median [25–75%] TIA: transient ischemic attack, eGFR: estimated glomerular filtration rate.
PVH: perivascular hyperintensity, DWMH: diffuse white matter hyperintensity, SLIs: silent lacunar infarcts, BNP: brain natriuretic peptide.
NIHSS: National Institutes of Health Stroke Scale, OACs: oral anticoagulants, CMBs: cerebral microbleeds, DOAC: direct oral anticoagulant, WF: warfarin.